imc a12
1 Recruiting Study Using IMC-A12 With or Without Cetuximab in Patients With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFr Therapy
Condition: Colorectal Cancer
Interventions: Drug: IMC-A12; Drug: IMC-A12 + cetuximab
2 Recruiting Study of IMC-A12, Alone or in Combination With Cetuximab, in Patients With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck
Condition: Head and Neck Cancer
Intervention: Biological: IMC-A12
3 Recruiting A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent
Conditions: Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET); Rhabdomyosarcoma; Leiomyosarcoma; Adipocytic Sarcoma; Synovial Sarcoma
Intervention: Biological: IMC-A12
4 Recruiting Study Using IMC-A12 or IMC-1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen-Independent Prostate Cancer, Following Disease Progression on Docetaxel-Based Chemotherapy
Condition: Metastatic Androgen-Independent Prostate Cancer
Intervention: Drug: IMC-1121B and IMC-A12
5 Recruiting IMC-A12 in Combination With Temsirolimus (CCI-779) in Patients With Advanced Cancers
Conditions: Advanced Cancers; Metastatic Cancer
Interventions: Drug: IMC-A12; Drug: Temsirolimus
6 Recruiting Monoclonal Antibody IMC-A12 and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous/Nonmalignant Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: anti-IGF-1R recombinant monoclonal antibody IMC-A12; Drug: temsirolimus
7 Not yet recruiting IMC-A12 and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: anti-IGF-1R recombinant monoclonal antibody IMC-A12; Drug: temsirolimus; Procedure: fluorescence in situ hybridization; Procedure: gene expression analysis; Procedure: immunohistochemistry staining method; Procedure: laboratory biomarker analysis; Procedure: mutation analysis; Procedure: pharmacological study; Procedure: proteomic profiling; Procedure: reverse transcriptase-polymerase chain reaction; Procedure: western blotting
8 Recruiting Monoclonal Antibody IMC-A12 and Doxorubicin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Conditions: Adult Malignant Fibrous Histiocytoma of Bone; Sarcoma
Interventions: Drug: anti-IGF-1R recombinant monoclonal antibody IMC-A12; Drug: doxorubicin hydrochloride
9 Recruiting IMC-A12 in Treating Patients With Advanced Liver Cancer
Condition: Liver Cancer
Intervention: Drug: anti-IGF-1R recombinant monoclonal antibody IMC-A12
10 Recruiting IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor
Conditions: Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: anti-IGF-1R recombinant monoclonal antibody IMC-A12; Procedure: pharmacological study; Procedure: protein expression analysis; Procedure: western blotting
11 Completed Study With IMC-A12 in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer
Condition: Adenocarcinoma of the Prostate
Intervention: Drug: IMC-A12
12 Recruiting A Study for Safety and Effectiveness of IMCA12 by Itself or Combined With Antiestrogens to Treat Metastatic Breast Cancer in Patients Who Progressed on Antiestrogen Therapy
Condition: Metastatic Breast Cancer
Intervention: Biological: IMC-A12
13 Recruiting Gemcitabine and Erlotinib With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Condition: Pancreatic Cancer
Interventions: Drug: anti-IGF-1R recombinant monoclonal antibody IMC-A12; Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
14 Not yet recruiting Capecitabine and Lapatinib With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
Condition: Breast Cancer
Interventions: Drug: anti-IGF-1R recombinant monoclonal antibody IMC-A12; Drug: capecitabine; Drug: lapatinib ditosylate
imc 1121b
1 Recruiting A Study of IMC-1121B in Combination With Paclitaxel and Carboplatin as First-Line Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Intervention: Biological: IMC-1121B
2 Recruiting Study Using IMC-A12 or IMC-1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen-Independent Prostate Cancer, Following Disease Progression on Docetaxel-Based Chemotherapy
Condition: Metastatic Androgen-Independent Prostate Cancer
Intervention: Drug: IMC-1121B and IMC-A12
3 Recruiting Study of IMC-1121B in Patients With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy
Condition: Hepatocellular Carcinoma
Intervention: Biological: IMC-1121B
4 Recruiting Safety Study of IMC-1121B With or Without Dacarbazine to Treat Metastatic Malignant Melanoma
Condition: Metastatic Malignant Melanoma
Intervention: Drug: IMC-1121
5 Recruiting Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma
Intervention: Biological: IMC-1121B
6 Recruiting Phase III Study of Docetaxel + IMC-1121B or Placebo in Breast Cancer
Condition: HER2 Negative Breast Cancer
Intervention: Biological: IMCL-1121B
7 Recruiting IMC-1121B in Patients With Metastatic Renal Cell Carcinoma With Disease Progression on or Intolerance to Tyrosine Kinase Inhibitor Therapy
Condition: Metastatic Renal Cell Carcinoma
Intervention: Drug: 1121B
